From Research to Practice: Training in Sexual and Reproductive Health Research

Strategies for data analysis: case-control studies

Eduardo Bergel

UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction World Health Organization






ЯR

Reproductive Health and Research



Design of case-control studies: retrospective





SHR Reproductive Health and Research



Examples of topics investigated by casecontrol studies

Exposure	Outcome
Use of oral contraceptives	Breast cancer
Recent use of oral contraceptives	Myocardial infarction
Large doses of folate and iron in pregnancy	Microcephaly
Phyto-oestrogens	Breast cancer
Male condom use	Genital warts

UNDP • UNFPA • WHO • World Bank Special Programme of Research, Development and Research Training In Human Reproduction

World Health Organization

Examples of topics investigated by casecontrol studies

Exposure	Outcome
Body mass index	Pancreatic cancer
Physical disability	Earthquake mortality
Hiatus hernia	Reflux oesophagitis
Paracetamol use	Ovarian cancer





SHR Reproductive Health and Research




Prevalence of disease is fixed by design

	Cases	Controls
Exposed	а	b
Non-exposed	С	d
	a+c	b+d
	Fixed marg	gins
World Health Organization	Reproductive Health and R	Research UNDP + UNF

UNDP . UNFPA . WHO . World Bank Special Programme of Research, Development and Research Training in Human Reproduction

wond nearth organization


Prevalence of disease is fixed by design



UNDP • UNFPA • WHO • World Bank Special Programme of Research, Development and Research Training in Human Reproduction

World Health Organization

Prevalence of disease is fixed by design



UNDP • UNFPA • WHO • World Bank Special Programme of Research, Development and Research Training in Human Reproduction

World Health Organization

Prevalence of exposure in cases and controls

In case-control studies we can calculate:
Prevalence of exposure in cases and in controls a/(a+c) and b/(b+d)

We cannot calculate prevalence of disease, or risk for exposed and for non-exposed

We cannot calculate the relative risk (RR)



Reproductive Health and Research



Odds of exposure

In case-control studies we can calculate:

• The odds ratio to measure association between disease and exposure:


The odds of being exposed for a case is a/c The odds of being exposed for a control is b/d

The odds ratio of exposure for cases vs controls is $OR_{Exp} = (a/c)/(b/d) = (a \times d)/(b \times c)$



SHR Reproductive Health and Research






Reproductive Health and Research

World Health Organization





 $ORExp = (a/c)/(b/d) = (a \times d)/(b \times c) = (a/b)/(c/d) = ORDis$



Reproductive Health and Research



Interpretation of the odds ratio

- If exposure and disease are not associated, OR=1
- If exposure and disease are positively associated, OR>1
- If exposure and disease are negatively associated, OR<1

The OR is a good estimation of the RR if the disease is rare



FRR Reproductive Health and Research



Confidence intervals for the OR

There are several methods: -Woolf's method: approximate -Cornfield method: iterative -Test-based method -Logistic regression

We usually work in the log scale, In OR Woolf's method:

SE In OR = $\sqrt{(1/a+1/b+1/c+1/d)}$

95% CI for ln OR: ln OR $\pm z_{0.025} \times \sqrt{(1/a+1/b+1/c+1/d)}$

95% CI for the OR: OR x exp $[\pm z_{0.025} \times \sqrt{(1/a+1/b+1/c+1/d)}]$



World Health Organization



Reproductive Health and Research



Strategy for data analysis for case-control studies

- Describe study profile: number of cases and controls, identified and analyzed
- Baseline characteristics of cases and controls
- Crude ORs for different categories of use and risk factors
- ORs for different categories of use and risk factors, adjusting for confounders





FIR Reproductive Health and Research



Example: Oral contraceptives and breast cancer in young women

Lancet 1985; 326:970-972

Study aim was to investigate relation between use of oral contraceptives (OCs) by young women and their risk of breast cancer.

Cases: women 20-44 years at initial diagnosis of breast cancer, between Dec 1 1980 and Dec 31 1982, resident in 8 regions of the US, identified from population-based cancer registries.

Controls: women 20-44 years selected during same 25 months as the cases were diagnosed, residents of the 8 regions, selected randomly by telephone calls to households.







Oral contraceptives and breast cancer Study profile: cases



6.4% refused to participate3.7% died or were too ill8.7% miscellaneous reasons






SHR Reproductive Health and Research



Oral contraceptives and breast cancer Study profile: controls



11.2% refused to participate2.2% moved out3.0% miscellaneous reasons



SHR Reproductive Health and Research



Oral contraceptives and breast cancer Baseline characteristics of cases and controls

	Cases(%)	Controls(%)
Age		
20-24	0.7	5.1
25-29	6.0	8.2
30-34	18.3	20.8
35-39	33.5	28.6
40-44	41.4	37.3
Family hist	tory of breast cance	r
Yes	29.1	18.7
No	42.3	51.4
Unknown	28.6	29.9



SHR Reproductive Health and Research



Oral contraceptives and breast cancer Baseline characteristics of cases and controls

		Cases(%)	Controls(%)
	Age at first to	erm pregna	ncy	
	Nulliparous	18.2		18.4
	<20	19.1		22.1
~	20-22	23.1		24.7
1	23-26	22.3		21.6
-	27-29	9.2		7.6
	>29	7.0		4.0
	Parous,			
	unknown ag	e 1.1		1.6
	Benign brea	st disease s	surgery	
	Yes	4.5		2.3
	No	87.2		91.7
	Unknown	8.3		6.0
-			ЯR	e hrp
	World Health Or	ganization	Reproductive Health and Research	UNDP • UNFPA • WHO • World Bank

Conclusions about baseline analysis

- Cases were older at diagnosis than controls were at selection
- Larger proportion of cases had family history of breast cancer
- Slightly larger proportion of cases had late age at first pregnancy
- Larger proportion of cases had benign breast disease surgery



FRR Reproductive Health and Research



Oral contraceptives and breast cancer Results: crude ORs

	Cases	Controls	
Exposed	1701	1662	
Non-exposed	387	403	OR=1.07
All	2088	2065	



SHR Reproductive Health and Research



The odds of being exposed for a case is 1701/387 = 4.4The odds of being exposed for a control is 1662/403 = 4.1

The odds ratio of exposed vs non-exposed is OR = (1701/387)/(1662/403) = $= (1701 \times 403)/(1662 \times 387) = 1.07$

95% CI: 0.91 to 1.25



Reproductive Health and Research



Stratification and confounding variables?

Age: main purpose was stratifying by age



Reproductive Health and Research



Oral contraceptives and breast cancer Results: crude ORs

Age at	Cases(%)		Controls(%)		
diagnosis or —					OR
selection	N	% ever	Ν	% ever	
		users		users	
20-24	15	100.0	106	69.8	-
25-29	126	86.5	169	87.6	0.91
30-34	382	89.3	429	88.1	1.13
35-39	700	86.4	590	85.1	1.11
40-44	865	73.0	771	72.6	1.02
Total	2088	81.5	2065	80.5	1.07
(da)					



Reproductive Health and Research

ЯR



Oral contraceptives and breast cancer results: adjusting

We need to adjust for factors associated with the risk of breast cancer or with the likelihood of diagnosis:

- Family history of breast cancer
- Age at first term pregnancy
- History of surgery for benign breast disease
- Frequency of breast examination

Techniques to adjust ORs:

- Logistic regression
- Mantel-Haenszel







Oral contraceptives and breast cancer Results: adjusted ORs

Age at	Cases(%)		Contro	ls(%)	
diagnosis					
or	-				OR(95% CI)
selection	N	% ever	Ν	% ever	(adjusted)
		users		users	
20-24	15	100.0	106	69.8	-
25-29	<mark>12</mark> 6	86.5	169	87.6	1.0 (0.5-2.1)
30-34	<mark>38</mark> 2	89.3	429	88.1	1.2 (0.7-1.8)
35-39	700	86.4	590	85.1	1.1 (0.8-1.6)
40-44	865	73.0	771	72.6	1.1 (0.9-1.4)
Total	2088	81.5	2065	80.5	

ЯR



World Health Organization

Reproductive Health and Research



Oral contraceptives and breast cancer Results: adjusted ORs

Use before					
first term	Cases	Controls	OR(95% CI)		
pregnancy	<mark>v N</mark>	Ν	(adjusted)		
Never	<mark>11</mark> 43	1174	1 (Reference)		
≤12	177	179	1.3 (1.0-1.7)		
13-48	323	336	1.1 (0.9-1.5)		
>48	231	208	1.2 (0.9-1.6)		
Total	1874	1897			
(ЯR	nrp		

UNDP + UNFPA • WHO • World Bank Special Programme of Research, Development and Research Training in Human Reproduction

World Health Organization

Oral contraceptives and breast cancer Conclusions

There was no significant increase or decrease in the risk of breast cancer for OC users according to

- Age at diagnosis
- Age at first use
- Duration of use
- Use before first term pregnancy

Use of OCs by young women in the US has no effect on the risk of breast cancer before 45 years of age



SHR Reproductive Health and Research



Thank you



SHR Reproductive Health and Research

